2297 Stock Overview
Operates as a vascular interventional surgical robotics company in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rainmed Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.18 |
| 52 Week High | HK$0.70 |
| 52 Week Low | HK$0.13 |
| Beta | 1.32 |
| 11 Month Change | 26.71% |
| 3 Month Change | 23.33% |
| 1 Year Change | -70.63% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2297 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 23.3% | -3.5% | -0.6% |
| 1Y | -70.6% | -39.2% | 9.6% |
Return vs Industry: 2297 underperformed the Hong Kong Medical Equipment industry which returned -39.2% over the past year.
Return vs Market: 2297 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 2297 volatility | |
|---|---|
| 2297 Average Weekly Movement | 18.1% |
| Medical Equipment Industry Average Movement | 9.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2297's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2297's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 266 | Yunfei Huo | rainmed.com |
Rainmed Medical Limited operates as a vascular interventional surgical robotics company in China and internationally. It engages in the research and development, manufacturing, and commercialization of medical instrument related to coronary angiography-derived fractional flow reserve (caFFR) systems and coronary angiography-derived index of microvascular resistance (caIMR) systems. The company offers caFFR systems comprising FlashAngio caFFR System and FlashPressure caFFR pressure transducer for a less-invasive physiological assessment of coronary artery ischemia severity based on coronary angiography images; and caIMR System, including FlashAngio caIMR System and FlashPressure caIMR pressure transducer, which is a less-invasive index of microcirculatory resistance measurement product for the treatment of microcirculatory lesions.
Rainmed Medical Limited Fundamentals Summary
| 2297 fundamental statistics | |
|---|---|
| Market cap | HK$216.04m |
| Earnings (TTM) | -HK$118.18m |
| Revenue (TTM) | HK$53.41m |
4.0x
P/S Ratio-1.8x
P/E RatioIs 2297 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2297 income statement (TTM) | |
|---|---|
| Revenue | CN¥49.71m |
| Cost of Revenue | CN¥19.76m |
| Gross Profit | CN¥29.96m |
| Other Expenses | CN¥139.95m |
| Earnings | -CN¥110.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.094 |
| Gross Margin | 60.26% |
| Net Profit Margin | -221.26% |
| Debt/Equity Ratio | 5.3% |
How did 2297 perform over the long term?
See historical performance and comparison